NCCN 15th Annual Conference Overview, Resources, and Upcoming Meetings


During the the National Comprehensive Cancer Network 15th Annual Conference, updates were presented for various NCCN Clinical Practice Guidelines.

The National Comprehensive Cancer Network (NCCN) 15th Annual Conference took place from Wednesday, March 10, to Sunday, March 14, at The Westin Diplomat in Hollywood, Florida. During the meeting, updates were presented for various NCCN Clinical Practice Guidelines, including colon cancer, breast cancer, cervical cancer, occult primary, acute myeloid leukemia, multiple myeloma, non-small cell lung cancer, esophageal cancer, and prostate cancer. New NCCN Guidelines were also presented for mesothelioma. All of the NCCN Clinical Practice Guidelines are available at

The NCCN Conference also featured two dynamic roundtable discussions, one focusing on end of life issues, which was moderated by Sam Donaldson, and one examining clinical and economic issues impacting cancer care delivery, which was moderated by Clifford Goodman, PhD. Between guideline updates, there were educational sessions, including on human papillomavirus and cancer risk, pharmacy in oncology, cancer in adolescents and young patients, new advances in molecular diagnostics, and management of treatment-related infections, thromboses, and neuropathy. To obtain a CD ROM from this meeting or other NCCN conferences, such as the NCCN 4th Annual Congress on Hematological Malignancies, visit

Interested in attending a NCCN meeting? The NCCN 5th Annual Congress on Hematological Malignancies will be taking place in New York City from October 8 to 9 at the New York Marriott Marquis. This Congress will “review multiple myeloma, chronic myelogenous leukemia, chronic lymphocytic leukemia, myelodysplasia and acute myeloid leukemia with respect to treatment at initial presentation, relapse, and when to consider bone marrow transplantation.”

For more information, visit, or to order enduring material from the NCCN 4th Annual Congress on Hematological Malignancies, visit

Related Videos
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Ghada Bourjeily, MD: Research Gaps on Sleep Issues During Pregnancy
John Winkelman, MD, PhD: When to Use Low-Dose Opioids for Restless Legs Syndrome
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
© 2024 MJH Life Sciences

All rights reserved.